Myb-transformed blood cells and their use for active ingredient screening

The invention relates to transformed blood cells and their use for active ingredient screening. The field of application of the invention are the pharmaceutical industry and medicine. It is the object of the invention to develop hematopoietic cells that are suitable for an active ingredient screenin...

Full description

Saved in:
Bibliographic Details
Main Authors BARTUNEK PETR, ZENKE MARTIN, DVORAK MICHAL, KARAFIAT VIT
Format Patent
LanguageEnglish
Published 03.06.2004
Edition7
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention relates to transformed blood cells and their use for active ingredient screening. The field of application of the invention are the pharmaceutical industry and medicine. It is the object of the invention to develop hematopoietic cells that are suitable for an active ingredient screening. It was found that v-Myb, a retrovirally transduced version of c-Myb, transforms primitive erythroid precursor cells (in the following designated as Myb/bFGF-cells) in the presence of the growth factor bFGF (basis fibroblast growth factor). The reason for this are both the features of v-Myb that are taken over from c-Myb, and new properties developed in interaction with bFGF. The invention is based on transformed blood cells for elucidation of factors, components that influence the formation and differentiation of blood cells, which are characterised in that they contain Myb, in particular v-Myb, and growth factors that interact with Myb.
Bibliography:Application Number: US20040471343